Short- and Long-Term Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Patients with Rheumatoid Arthritis and an Inadequate Response to TNF Inhibitors: Analyses of Pooled Phase 2, Phase 3, and Long-Term Extension Studies.

被引：0
|
作者：
Burmester, G. [1 ]
Blanco, Ricardo [2 ]
Rubbert-Roth, Andrea [3 ]
Hendrikx, Thijs [4 ]
Kwok, Kenneth [5 ]
Bradley, John [6 ]
Zwillich, Samuel H. [6 ]
Benda, Birgitta [7 ]
Mebus, Charles A. [6 ]
机构：
[1] Charite, D-13353 Berlin, Germany
[2] Hosp Univ Marques De Valdecilla, Santander, Spain
[3] Univ Cologne, D-50931 Cologne, Germany
[4] Pfizer Bv, Capelle Aan Den Ijssel, Netherlands
[5] Pfizer Inc, New York, NY USA
[6] Pfizer Inc, Groton, CT 06340 USA
[7] Pfizer Inc, Collegeville, PA USA
来源：
ARTHRITIS AND RHEUMATISM | 2012年 / 64卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
L12
引用
收藏
页码：4172 / 4172
页数：1
相关论文
共 50 条
  • [31] SEX DIFFERENCES IN THE EFFICACY AND SAFETY OF TOFACITINIB IN RHEUMATOID ARTHRITIS PATIENTS: A POST HOC ANALYSIS OF PHASE 3 AND LONG-TERM EXTENSION TRIALS
    Jones, H. N.
    Strand, V.
    Schulze-Koops, H.
    Mysler, E.
    Kinch, C.
    Gruben, D. C.
    Germino, R.
    Connell, C. A.
    Eder, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 565 - 566
  • [32] Sex Differences in the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis Patients: A Post Hoc Analysis of Phase 3 and Long-Term Extension Trials
    Jones, Niall
    Strand, Vibeke
    Schulze-Koops, Hendrik
    Mysler, Eduardo
    Kinch, Cassandra D.
    Gruben, David
    Germino, Rebecca
    Connell, Carol A.
    Eder, Lihi
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [33] Sex Differences in the Efficacy and Safety of Tofacitinib in Patients With Rheumatoid Arthritis: A Post Hoc Analysis of Phase 3 and Long-Term Extension Trials
    Jones, Niall
    Strand, Vibeke
    Schulze-Koops, Hendrik
    Mysler, Eduardo
    Kinch, Cassandra
    Gruben, David
    Germino, Rebecca
    Connell, Carol
    Eder, Lihi
    JOURNAL OF RHEUMATOLOGY, 2021, 48 (07) : 1145 - 1145
  • [34] Baricitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: 52 Week Safety and Efficacy in an Open-Label, Long-Term Extension Study
    Baker, Milton
    Chalabi, Youb
    Genovese, Mark
    Taylor, Peter
    Schlichting, Douglas
    Beattie, Scott
    Macias, William
    Keystone, Edward
    JOURNAL OF RHEUMATOLOGY, 2014, 41 (07) : 1505 - 1505
  • [35] Evaluation of the Short-, Mid-, and Long-Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis
    van Vollenhoven, Ronald
    Lee, Eun Bong
    Strengholt, Sander
    Mojcik, Christopher
    Valdez, Hernan
    Krishnaswami, Sriram
    Biswas, Pinaki
    Lazariciu, Irina
    Hazra, Anasuya
    Clark, James D.
    Hodge, Jennifer
    Wang, Lisy
    Choy, Ernest
    ARTHRITIS & RHEUMATOLOGY, 2019, 71 (05) : 685 - 695
  • [36] Long-term efficacy and safety of a repeat treatment course of rituximab in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors.
    Keystone, E.
    Fleischmann, R. M.
    Emery, P.
    Chubick, A.
    Dougados, M.
    Baldassare, A. R.
    Bathon, J. M.
    Hessey, E.
    Totoritis, M.
    Cooper, S.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S328 - S328
  • [37] Tofacitinib (CP-690,550), An Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Open-Label, Long-Term Extension Studies up to 36 Months.
    Wollenhaupt, J.
    Silverfield, J. C.
    Lee, E. B.
    Wood, S.
    Soma, K.
    Wang, L.
    Nakamura, H.
    Komuro, Y.
    Nduaka, C. I.
    Gruben, D.
    Zwillich, S. H.
    Bradley, J. D.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S152 - S153
  • [38] Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis
    Charles-Schoeman, Christina
    DeMasi, Ryan
    Valdez, Hernan
    Soma, Koshika
    Hwang, Lie-Ju
    Boy, Mary G.
    Biswas, Pinaki
    McInnes, Iain B.
    ARTHRITIS & RHEUMATOLOGY, 2019, 71 (09) : 1450 - 1459
  • [39] Analysis of Infections and All-Cause Mortality in Phase II, Phase III, and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis
    Cohen, Stanley
    Radominski, Sebastiao C.
    Gomez-Reino, Juan J.
    Wang, Lisy
    Krishnaswami, Sriram
    Wood, Susan P.
    Soma, Koshika
    Nduaka, Chudi I.
    Kwok, Kenneth
    Valdez, Hernan
    Benda, Birgitta
    Riese, Richard
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 (11) : 2924 - 2937
  • [40] LONG-TERM EFFICACY OF TOCILIZUMAB UP TO 3.5 YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS: AN INTERIM ANALYSIS OF LONG-TERM EXTENSION STUDIES
    Calvo, A.
    Sid, D.
    Saavedra, M.
    Kissel, K.
    Alecock, E.
    Smolen, J.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2010, 16 (03) : S34 - S34
12345